OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical ...
Servier exercised first of two steps under OSE-127 global licensing option agreement OSE-127, an IL-7R antagonist, is currently in Phase 1 clinical testing NANTES, France and PARIS, Feb. 07, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: …